Behind the Barrier: Targeting Immune Signals in Glioblastoma

Glioblastoma is one of the most aggressive and deadly forms of brain cancer, known for its rapid progression and resistance to treatment. Professor Louis Burton Nabors and Dr Natalia Filippova at the University of Alabama have highlighted the role of the immune system in this cancer, and in particular, a receptor called TREM1, which is involved in disease severity and progression. They developed a novel compound called SRI42127, which can block this pathway and reduce tumour growth in laboratory experiments. Their work shows that targeting the tumour’s immune support network may offer a promising new approach to developing effective therapies.